CHGG vs SKIN
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
Chegg is in a state of severe financial distress, evidenced by a critical Piotroski F-Score of 2/9 and a catastrophic YoY revenue decline of 49.40%. While the stock trades at a low Price/Sales ratio (0.31) and near book value (P/B 0.96), these valuation metrics are deceptive given the rapid erosion of the core business model. Liquidity is tightening with a current ratio of 0.86, and the company has transitioned from a consistent earnings-beater to a loss-making entity. The technical trend is fully bearish, and the fundamental decay outweighs any speculative analyst price targets.
The Beauty Health Company (SKIN) presents a high-risk profile characterized by a stable Piotroski F-Score of 5/9 but severely compromised financial health. While valuation metrics like Price/Sales (0.39) and Forward P/E (8.30) appear attractive, they are overshadowed by an extreme Debt/Equity ratio of 6.20 and negative revenue growth. The stock is in a severe long-term downtrend, losing over 90% of its value over 3 and 5 years, suggesting the market is pricing in significant solvency or growth risks.
Compare Another Pair
Related Comparisons
CHGG vs SKIN: Head-to-Head Comparison
This page compares Chegg, Inc. (CHGG) and The Beauty Health Company (SKIN) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.